AELIX's HIV Vaccine Assets Acquired by Gilead Sciences
Deal News | Nov 25, 2024 | Ysios Capital
Gilead Sciences, a leader in HIV treatment, has acquired the HTI HIV investigational assets of AELIX Therapeutics. AELIX is a Barcelona-based biotech company focused on developing therapeutic HIV vaccines. This acquisition is significant as AELIX's vaccine candidates have showed promising results in early phase clinical trials. The acquisition by Gilead is expected to further the potential of these assets in HIV cure strategies. Thomas Hecht, Executive Chairman of AELIX, expressed excitement about the acquisition, praising the early support from investors like Ysios Capital. Christian Brander, AELIX's CSO, noted the role of innovative research conducted at IrsiCaixa that led to the vaccine's development.
Sectors
- Biopharmaceutical
- Private Equity
Geography
- Spain – AELIX Therapeutics is based in Barcelona, Spain, making this the central geography of the biopharmaceutical development discussed.
- United States – Gilead Sciences, the acquiring company, is headquartered in Foster City, California, USA, establishing a cross-border element to the transaction.
Industry
- Biopharmaceutical – This article involves AELIX Therapeutics and Gilead Sciences, both of which operate in the biopharmaceutical industry, focusing on the development and commercialization of innovative medical treatments and vaccines.
- Private Equity – Ysios Capital, a private equity firm, is mentioned as one of the early-stage investors in AELIX, highlighting the role of financial backing in the biopharmaceutical sector.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| AELIX Therapeutics | Target Company | Company | A clinical stage biotechnology company focused on therapeutic HIV vaccine development, based in Barcelona, Spain. |
| Gilead Sciences, Inc. | Bidding Company | Company | A leading American biopharmaceutical company engaged in research and development of HIV treatments. |
| Ysios Capital | Investor | Company | A private equity firm based in Spain that invested early in AELIX Therapeutics. |
| Christian Brander | CSO and Co-founder of AELIX | Person | Discovered the HTI immunogen with colleagues, contributing significantly to AELIX's vaccine development. |
| Thomas Hecht | Executive Chairman of AELIX | Person | Provided leadership during the development of AELIX's HTI HIV vaccine assets. |